| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 05/18/2022 | 372.59% | Piper Sandler | $34 → $25 | Maintains | Overweight |
| 06/30/2021 | 296.98% | B. Riley Securities | $41 → $21 | Maintains | Buy |
| 06/30/2021 | 486.01% | JMP Securities | $53 → $31 | Maintains | Market Outperform |
| 06/30/2021 | 372.59% | HC Wainwright & Co. | $35 → $25 | Maintains | Buy |
| 06/16/2021 | 901.89% | JMP Securities | $45 → $53 | Maintains | Market Outperform |
| 06/02/2021 | 561.63% | HC Wainwright & Co. | → $35 | Initiates Coverage On | → Buy |
| 02/11/2021 | 580.53% | Guggenheim | → $36 | Initiates Coverage On | → Buy |
| 11/24/2020 | 372.59% | Evercore ISI Group | → $25 | Reinstates | → Outperform |
| 09/25/2020 | 486.01% | B. Riley Securities | → $31 | Initiates Coverage On | → Buy |
| 07/31/2020 | 1412.29% | Piper Sandler | → $80 | Initiates Coverage On | → Overweight |
| 07/28/2020 | 845.18% | JMP Securities | → $50 | Initiates Coverage On | → Market Outperform |
| 07/19/2019 | 56.9% | Roth Capital | → $8.3 | Initiates Coverage On | → Buy |
| 10/09/2017 | 13.42% | Piper Sandler | → $6 | Initiates Coverage On | → Overweight |
Altimmune Questions & Answers
The latest price target for Altimmune (NASDAQ: ALT) was reported by Piper Sandler on May 18, 2022. The analyst firm set a price target for $25.00 expecting ALT to rise to within 12 months (a possible 372.59% upside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for Altimmune (NASDAQ: ALT) was provided by Piper Sandler, and Altimmune maintained their overweight rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Altimmune, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Altimmune was filed on May 18, 2022 so you should expect the next rating to be made available sometime around May 18, 2023.
While ratings are subjective and will change, the latest Altimmune (ALT) rating was a maintained with a price target of $34.00 to $25.00. The current price Altimmune (ALT) is trading at is $5.29, which is out of the analyst's predicted range.